Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
PTC Therapeutics to Participate at Upcoming Investor Conferences
08:00am, Thursday, 24'th Apr 2025
WARREN, N.J. , April 24, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Bank of America Securities 2025 Health
PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy?
11:05am, Thursday, 17'th Apr 2025
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
08:00am, Thursday, 17'th Apr 2025
WARREN, N.J. , April 17, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2025 financial res
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 28'th Mar 2025
WARREN, N.J. , March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 24, 2025, the company approved non-statutory stock options to purchase an aggregate o
PTC Therapeutics says European Commission will remove muscle disorder drug
09:20am, Friday, 28'th Mar 2025
PTC Therapeutics said on Friday the European Commission will remove its inherited progressive muscle-wasting disorder from the region after an advisory panel reaffirmed a negative opinion of the drug
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe
09:00am, Friday, 28'th Mar 2025
WARREN, N.J. , March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
08:00am, Thursday, 20'th Mar 2025
— Results show 97% of phenylalanine (Phe) tolerance study participants were able to increase their dietary Phe intake with a mean increase of 126% — — Genetic variant analysis of Phase 3 APHENI
PTC Therapeutics: Upside In Rare Disease Innovation
09:47am, Sunday, 09'th Mar 2025
PTC Therapeutics is poised for a potential turnaround with key FDA reviews in 2025 for vatiquinone and sepiapterin, despite past revenue declines. The company maintains a strong cash position of over
PTC Therapeutics, Inc. (PTCT) Q4 2024 Earnings Call Transcript
09:41pm, Thursday, 27'th Feb 2025
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Head of IR Matthew Klein - CEO Eric Pauwels - Chief Business O
PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say
06:31pm, Thursday, 27'th Feb 2025
Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates
06:15pm, Thursday, 27'th Feb 2025
PTC Therapeutics (PTCT) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to loss of $0.24 per share a year ago.
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
04:01pm, Thursday, 27'th Feb 2025
– Full year 2024 revenue of $807 million, exceeding guidance – – All 2024 clinical and regulatory milestones were achieved on schedule, including four NDA submissions, all of which were accepted
Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
10:22am, Monday, 24'th Feb 2025
Besides Wall Street's top -and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared duri
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Thursday, 20'th Feb 2025
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Thursday, 20'th Feb 2025
WARREN, N.J. , Feb. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at the following investor conferences: TD Cow
